ESMO Congress News

[Palex80]

1. Patients with primary metastatic nasopharyngeal cancer benefit from RT to the primary disease after response to first line chemotherapy.

Annals of Oncology | Journal | ScienceDirect.com by Elsevier

Read the latest articles of Annals of Oncology at ScienceDirect.com, Elsevier’s leading platform of peer-reviewed scholarly literature

academic.oup.com

2. Oligometastatic prostate cancer patients that benefit the most from RT to the primary may be those with up to 3 bone lesions & no visceral metastasis, independent of nodal disease.

Annals of Oncology | Journal | ScienceDirect.com by Elsevier

Read the latest articles of Annals of Oncology at ScienceDirect.com, Elsevier’s leading platform of peer-reviewed scholarly literature

academic.oup.com

---

Members don't see this ad.

 

[evilbooyaa]

First one in a randomized (albeit phase II) trial was crazy to me (saw it on twitter of all places). Thanks for posting.

Second one I'm not surprised about. Visceral mets always were bad in prostate CA